A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

Trial Profile

A Randomized, Double-Blind, Active-Controlled, Phase 3 Study to Evaluate the Safety and Efficacy of CCX168 (Avacopan) in Patients with Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/Azathioprine

Recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Apr 2018

At a glance

  • Drugs Avacopan (Primary) ; Azathioprine; Cyclophosphamide; Cyclophosphamide; Prednisone; Rituximab
  • Indications Anti-neutrophil cytoplasmic antibody-associated vasculitis
  • Focus Therapeutic Use
  • Acronyms ADVOCATE
  • Sponsors ChemoCentryx
  • Most Recent Events

    • 11 Apr 2018 According to a ChemoCentryx media release, positive safety, efficacy and quality of life results from this study are being presented during the 2018 Spring Clinical Meetings of the National Kidney Foundation (NKF).
    • 09 Mar 2018 According to a ChemoCentryx Inc. media release, this trial has reached close to 75% of the target enrollment.
    • 07 Nov 2017 According to a ChemoCentryx media release, this trial has surpassed 30% of its target patient enrollment.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top